KR20140135488A - Antioxidant composition comprising cockscome flower extracts - Google Patents
Antioxidant composition comprising cockscome flower extracts Download PDFInfo
- Publication number
- KR20140135488A KR20140135488A KR20130055827A KR20130055827A KR20140135488A KR 20140135488 A KR20140135488 A KR 20140135488A KR 20130055827 A KR20130055827 A KR 20130055827A KR 20130055827 A KR20130055827 A KR 20130055827A KR 20140135488 A KR20140135488 A KR 20140135488A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- flower
- water
- bhp
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 17
- 239000003963 antioxidant agent Substances 0.000 title description 8
- 230000000694 effects Effects 0.000 claims abstract description 17
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 8
- 229930003935 flavonoid Natural products 0.000 claims abstract description 7
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 7
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 210000004185 liver Anatomy 0.000 claims description 12
- 241000561734 Celosia cristata Species 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 235000012041 food component Nutrition 0.000 claims description 2
- 241000570861 Mandragora autumnalis Species 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 abstract description 17
- 241000255789 Bombyx mori Species 0.000 abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 230000005779 cell damage Effects 0.000 abstract description 6
- 208000037887 cell injury Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 28
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- -1 superoxide radicals Chemical class 0.000 description 8
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert-Butyl hydroperoxide Substances CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 8
- 244000236480 Podophyllum peltatum Species 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 6
- 229960004245 silymarin Drugs 0.000 description 6
- 235000017700 silymarin Nutrition 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 5
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 150000005839 radical cations Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- LJJZKMDEQVYRJX-UHFFFAOYSA-N 4,5,6-tripyridin-2-yltriazine Chemical compound N1=CC=CC=C1C1=NN=NC(C=2N=CC=CC=2)=C1C1=CC=CC=N1 LJJZKMDEQVYRJX-UHFFFAOYSA-N 0.000 description 2
- WPBZMCGPFHZRHJ-UHFFFAOYSA-N 4-aminobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N)C=C1 WPBZMCGPFHZRHJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000282537 Mandrillus sphinx Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- SXSXOQFGUZXAEK-OJUPNBFJSA-N N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O SXSXOQFGUZXAEK-OJUPNBFJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition having an antioxidative activity effect using an extract of Mamlami flower as an active ingredient.
According to the present invention, it is possible to prevent the cell damage due to oxidative stress and also to prevent the cell damage caused by the active oxygen generated by the oxidative stress, by using the extract of Bombyx mori, which contains polyphenol and flavonoid, It has the effect of treating and preventing diseases.
Description
The present invention relates to a composition having an antioxidative activity effect using an extract of Mamlami flower as an active ingredient.
Oxidation is essential for the production of energy to fuel the biological processes of living organisms, but free radicals and reactive oxygen species (ROS), which are constantly produced in vivo, lead to cell death and tissue damage (Turkoglu, Duru , Mercan, Kivrak, & Gezer, 2007).
Oxidative stress appears to be an imbalance between the production of reactive oxygen species and the antioxidant defense system of cells. Excessive production of reactive oxygen species causes oxidative stress, loss of cell function, ultimately apoptosis or necrosis. Oxidative stress caused by active oxygen species induces chronic diseases, so antioxidative activity or free radicals Inhibition is very important in protecting cells from toxic substances caused by oxidative stress.
(2002) reported that patients with atherosclerotic lesions were more likely to develop atherosclerosis than those with atherosclerotic disease (Halliwell et al., 1994; Darley-Usmar, Wiseman, & Halliwell, 1995), cancer (Halliwell et al., 1994; Eze, Hunting, , And Samman, 1996), diabetes (Lee et al., 2006), malaria (Dey, Duha, Alam, Goyal, Bindu, Pal et al., 2009; Eze, Yuan, Crawford, Paranavitana, Hadfield, Bhattacharjee, (Rattan, 2006; Eze, < RTI ID = 0.0 > Eze, < / RTI > 2007) and HIV / AIDS (Pocernich, Sultana, Mohmmad-Abdul, Nath, & Butterfield, 2005; Masia, Padilla, Bernal, Almenar, Molina, 2006).
The liver plays an important role in maintaining systemic lipid homeostasis and is inherently vulnerable to ROS damage (Aruoma, 1994). Meanwhile, the liver plays an important role in detoxification as well as supplying energy substrates to surrounding tissues through Cori cycle / glycogen catabolism (Hamelet, Demuth, Paul, Delabar, & Janel, 2007). Oxidative stress-related factors may be associated with liver dysfunction, and liver dysfunction is associated with oxidation of nutrients (Yang, Li, Shi, & Le, 2008). In addition, ROS has deleterious effects on liver cells by damaging DNA, lipids and proteins, destroying cellular homeostasis and exacerbating features of metabolic syndrome (Ravel, Lymas, Nitta, Mohuczy, Lemaster, Kim et al., 2006; Kohen, & Nyska, 2002).
Studies on antioxidants have been carried out in 1969 when McCord and Fridovich discovered SOD, an enzyme that clears superoxide radicals. In recent years, diseases such as aging and adult diseases have been associated with active oxygen, , And research on natural antioxidants using plant extracts has attracted much attention because of the potential side effects of synthetic antioxidants.
Korean Patent No. 10-0881035 (composition for the treatment and prevention of human diseases due to viruses containing mandrami extract), Korean Patent No. 10-1081059 (having antioxidative and whitening activity) And a cosmetic composition containing the flower blend extract thereof). However, the technical feature of using the extract of Bombyx mori as an antioxidant composition to prevent cell damage from oxidative stress has not been disclosed.
It is an object of the present invention to provide a composition having an antioxidative activity effect using an extract extracted from Bombyx mori as an active ingredient.
In order to accomplish the above object, the present invention provides a composition having an antioxidative activity effect using an extract of Celosia cristata L. as an active ingredient.
The mandrake flower extract is characterized by containing polyphenols and flavonoids.
The composition of the present invention is characterized in that it comprises 0.1 to 50% by weight of a mandrake flower extract.
The Mandrel flower extract comprises (1) washing and freeze-drying Celosia cristata L. by removing seeds; (2) adding water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof to the lyophilized dried flower of the mandrmia flower; And (3) filtering the extract of the extracted Mandra flower to evaporate the filtrate and freeze-dry the extract.
At this time, in step (2), the mixture of the powder of Mandrel flower and water, the lower alcohol having 1 to 4 carbon atoms or the mixed solvent thereof is mixed with 8: 1 to 12: 1 (g / L) and extracted.
The composition is further characterized by being used as a health functional food, further comprising a pharmaceutically acceptable extract, a nutritional ingredient or a food auxiliary additive.
The composition may further comprise a pharmaceutically acceptable carrier or excipient to be used as a drug effective for liver protection.
According to the present invention, it is possible to prevent the cell damage due to oxidative stress and also to prevent the cell damage caused by the active oxygen generated by the oxidative stress, by using the extract of Bombyx mori, which contains polyphenol and flavonoid, It has the effect of treating and preventing diseases.
Figure 1 shows the effect of CCF water extract on viability of Chang cells.
Figure 2 shows the cell cycle of Chang cells treated with CCF water extract prior to t-BHP treatment.
Figure 3 shows the effect of CCF water extract on MMP loss caused by t-BHP in Chang cells. (a) Control; (b) t- BHP (80 [mu] M); (c) t- BHP (80 [mu] M) + 0.05 mg / mL CCF water extract; (d) t- BHP (80 [mu] M) + 0.1 mg / mL water extract; (e) t- BHP (80 [mu] M) + 0.2 mg / mL water extract; (f) t- BHP (80 [mu] M) + 0.05 mg / mL silymarin
Figure 4 shows changes in intracellular ROS produced by t-BHP in Chang cells.
Hereinafter, the present invention will be described in detail.
In the present invention, CCF ( Celosia cristata L. flower) refers to Mandrel flower belonging to the genus Vernia. Celosia cristata L. belongs to the genus Bacillus and has edible leaves and flowers. Its seeds are used for the treatment of fatigue, atherosclerosis, hypertension, hypertension, stroke, cataract, keratitis, diabetes, iritis, osteoporosis. Was used as
The present invention provides a composition having an antioxidative activity effect using an extract of Celosia cristata L. as an active ingredient.
The Mandra flower extract preferably contains polyphenols and flavonoids, and the composition preferably contains Mandrake flower extract in an amount of 0.1 to 50% by weight.
The Mandrel flower extract comprises (1) washing and freeze-drying Celosia cristata L. by removing seeds; (2) adding water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof to the lyophilized dried flower of the mandrmia flower; And (3) filtering the extract of the extracted Mamlami flower to evaporate the filtrate and lyophilize it.
In step (2), it is preferable to mix and mix water and water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof in an amount of 8: 1 to 12: 1 (g / L) It is most effective to extract water by adding water having a volume of 90 to 110 times the weight of the powder, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
The composition can be used for the treatment and prevention of diseases caused by oxides produced by active oxygen, and is particularly effective for liver protection.
The composition may further comprise a pharmaceutically acceptable extract, a nutritional component or a food-aid additive and may be used as a health functional food.
The composition may further comprise a pharmaceutically acceptable carrier or excipient and may be used as a drug effective for liver protection.
As a result of in vitro and in vivo experiments using t- BHP ( tert- butyl hydroperoxide) in order to confirm the antioxidative effect of the extracts of Mandrel flowers, It was confirmed that the antioxidant activity such as elimination of oxygen system and prevention of lipid peroxidation has an effect of preventing cell damage caused by oxidative stress.
t-BHP is a widely used oxidant in in vitro and in vivo experiments to induce oxidative stress. t-BHP is metabolized by cytochrome P-450 in the liver cells or hemoglobin in red blood cells to free radical intermediates such as t-butoxyl, -methyl radicals, leading to lipid peroxidation, reduced glutathione (GSH) and DNA damage.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
Example 1 Preparation of Water Extract and Ethanol Extract of Mandrake Flower (CCF)
Celosia cristata L. flowers were obtained, seeds were removed, washed, lyophilized under reduced pressure, and each extract was prepared with water and ethanol having a concentration of 70%.
The water extract was prepared by adding 10 g of Mandrel flower powder to 1 L of water, stirring at 95 캜 for 2 hours, and then evaporating by filtration. The ethanol extract was prepared by mixing 10 g of Mandrel flower powder with 1 L of ethanol having a concentration of 70% The mixture was extracted twice with reflux. 41 filter paper, and the filtrate was evaporated to an evaporator (EYELA, Tokyo, Japan) so that all of the solvent was evaporated at 50 ° C.
The evaporated water and the ethanol extract were lyophilized under reduced pressure and stored at -20 ° C. The yields of water and ethanol extracts were 144 and 202.4 mg / g, respectively (see Table 1).
Experimental Example 1. Measurement of content of polyphenols and flavonoids
The content of phenolic substances in Bombyx mori was determined by Folin-Ciocalteau assay. Specifically, an aqueous solution was prepared by dissolving 10 mg of each Mamlami flower extract in 10 mL of distilled water. To each 0.1 mL aqueous solution was added 50 μL of 50% Folin-Ciocalteau and 150 μL of 20% sodium carbonate (Na 2 CO 3 ) ≪ / RTI > Thereafter, the mixture was stirred at room temperature for 30 minutes, and the absorbance of the reaction product was measured at 760 nm using a spectrophotometer (SECOMAM, Ales, France).
The content of flavonoids in Bombyx mori L. extract was measured by slightly modified aluminum colorimetric method. Specifically, each of the mamdum flower extracts was dissolved in distilled water to prepare an aqueous solution. Each 150 μL aqueous solution was mixed with 45 μL of 5% sodium nitrite (NaNO 2 ) and allowed to react for 5 minutes. Then, 90 μL of 10% aluminum chloride (AlCl 3 ) was added and reacted for 5 minutes. Thereafter, 300 μL of 1 M sodium hydroxide (NaOH) and 165 μL of distilled water were added and reacted at ambient temperature for 10 minutes , And the absorbance of the supernatant was measured at 510 nm using a spectrophotometer.
As a result, the total amount of polyphenol was 58.36 ± 1.29 mg GAE / g extract in the water extract, 67.55 ± 1.15 mg GAE / g extract in the ethanol extract, 15.92 ± 1.46 mg CE / g extract in the water extract, 25.92 + 2.21 mg CE / g extract was measured (see Table 1).
Experimental Example 2. Free Radical Scavenging Ability of Mandrake Flower Extract
1. DPPH radical scavenging ability
DPPH radical scavenging activity was measured using an ESR spectrometer (JES-FA machine; JOEL, Tokyo, Japan). 60 μL of each sample was added to 60 μL of 60 μM DPPH, vigorously mixed for 10 seconds, transferred to a Teflon capillary and fixed in the cavity of the ESR spectrometer. The spin adduct was recorded exactly two minutes after the central field at 3,475 G, a modulation frequency of 100 kHz, an amplitude modulation of 2 G, a microwave power of 5 mW, a gain of 6.3 × 10 5 and a temperature of 298 K .
As a result, Mandrake flower extract scavenged DPPH radicals in a dose-dependent manner and showed strong DPPH radical scavenging ability. Water and ethanol extracts showed similar DPPH radical scavenging ability compared to vitamin C (see Table 2).
2. Alkyl radical scavenging ability
The alkyl radical is generated by AAPH. 40 mM AAPH, 40 mM 4-POBN and PBS (phosphate-buffered saline, pH 7.4) containing each sample were reacted in a 37 ° C water bath for 30 minutes and transferred to a Teflon capillary. Spin adducts were recorded by an ESR spectrometer at a central field of 3,475 G, a modulation frequency of 100 kHz, an amplitude modulation of 2 G, a microwave power of 1 mW, a gain of 6.3 × 10 5 and a temperature of 298 K .
The alkyl radical spin adduct of 4-POBN / free radicals originated from AAPH, and a decrease in ESR signal was observed in a dose-dependent manner in all extracts. Water and ethanol extracts showed higher alkyl radical scavenging ability compared to vitamin C (see Table 2).
EXPERIMENTAL EXAMPLE 3 ABTS radical scavenging ability of Bombyx mori extract
The antioxidative activities of water and ethanol extracts of Bombyx mori were determined by ABTS . + Radical cation decolorization assay.
ABTS was dissolved in water at a concentration of 7 mM. ABTS radical cation (ABTS . + ) Was produced by mixing 2.45 mM potassium persulfate (K 2 S 2 O 8 ) with ABTS stock solution and allowing the mixture to stand at room temperature for 14 hours. The oxidation of ABTS began immediately, but the absorbance was stable, not the maximum, until more than 6 hours had elapsed, while the radical cation was stable during storage for more than 2 days at room temperature. The stable radical cation solution was diluted with ethanol to an absorbance value of 1.50 ± 0.02 at 734 nm, 0.9 mL of ABTS was mixed with 0.1 mL of each sample, reacted at room temperature for 6 minutes, and absorbance was measured at 734 nm. The antioxidative activity of Mandrake flower extract was expressed as mM Trolox eq./mg extract.
The scavenging ability of Bombyx mori L. extract against ABTS radicals induced by potassium persulfate was compared with the standard amount of Trolox. The water extracts showed higher TEAC values than the ethanol extracts and the Mandrill flower extracts showed strong ABTS radical scavenging ability (see Table 3).
Experimental Example 4 Ferric reducing antioxidant power (FRAP)
A mixture of 3 mL of FRAP reagent and 0.3 M of acetate buffer, 10 mM of TPTZ contained in 40 mM of HCl, and 20 mM of ferric chloride in a ratio of 10: 1: 1 (v / v / v) Was mixed with 1 mL of each sample. Absorbance values were expressed as mM FeSO 4 eq./mg extract as compared to those obtained from a standard curve of FeSO 4 (0-10 mM).
The antioxidant capacity of Bombyx mori was determined from its ability to reduce TPRZ (tripyridyl triazine) -Fe (Ⅲ) complex to TPTZ (tripyridyl triazine) -Fe (Ⅱ) complex (see Table 3).
Hereinafter, the DPPH IC 50 , the alkyl IC 50 , In vitro and in vivo experiments were carried out on water extracts of Bombyx mori L. on the basis of ABTS and FRAP values.
Experimental Example 5. Cell Culture and Experiment
Chang liver cells purchased from the American Type Culture Collection (ATCC CCL-13 TM ) were incubated with 10% fetal bovine serum, streptomycin (100 μg / mL) and penicillin (penicillin, 100 unit / mL) (95% air, 5% carbon dioxide) at 37 [deg.] C in the DMEM medium containing the cells. Adherent cells were separated by trypsin-EDTA to have a confluence of 70-80% on 6 or 96 well plates. Then, each sample was dissolved in distilled water to a concentration of 0.5, 1, 2 mg / mL, and cells having the above density were treated with various concentrations of water extract (final concentration: 0.05, 0.1, 0.2 mg / mL).
The liver protective effects of water extracts of Bombyx mori L. flowers were tested based on the cytotoxicity of t-BHP which generates alkoxyl / peroxyl radicals which cause oxidative stress in the cell system.
1. Cell Viability
Cell viability was measured by MTT assay, which tests the metabolism of cells by measuring the activity of mitochondria.
Chang liver cells were inoculated into 96-well plates at a concentration of 4.0 × 10 5 cells / mL. After 20 hours, the concentration of the water extract of Bombyx mori was variously treated and incubated in a humidified incubator at 37 ° C for 1 hour. Then, t-BHP was added to a final concentration of 80 μM and cultured for 24 hours. Then, 100 μL of stock solution of 0.5 mg / mL was added and incubated for 4 hours. Finally, the supernatant was inhaled to dissolve each formazan crystal in 150 μL of DMSO, (SpectraMax M2 / M2e, CA, USA) at 540 nm. Cell viability was measured by the amount of MTT converted to insoluble formazan salt.
Based on the results of the MTT assay, which showed no significant toxicity for 24 hours, up to 0.2 mg / mL of Changmy flower extract showed 55.98 ± 4.25% survival of Chang cells treated with t-BHP (80 μM) for 24 hours (CCF 0.05 mg / mL) and 79.12 ± 3.98% (CCF 0.1 mg / mL, respectively) were treated with CCF water extract for 1 hour and treated with t-BHP ) And 88.98 ± 5.41% (CCF 0.2 mg / mL). The cell viability obtained by pretreatment with 0.05 mg / mL of silymarin in the positive group was also increased to 89.87 ± 2.98% (see FIG. 1).
Silymarin has been used as a treatment for long-term liver diseases due to the effect of preventing hepatic damage, which can modify the cytoplasmic membrane to form t-BHP, carbon tetrachloride (CCl 4 ), thioacetamide, D-galactosamine (D- galactosamine) to prevent liver damage.
It was confirmed that the treatment of Mandrel flower extract with a cytotoxic concentration (0.2 mg / mL) increased the viability of Chang cells exposed to t-BHP causing oxidative stress and showed excellent liver protection effect.
2. Cell cycle analysis using flow cytometry
Cells were collected, washed twice with PBS buffer (pH 7.4), fixed with 80% ethanol overnight, washed twice with PBS, and then incubated with 50 μg / ml PI and 5 μg / And resuspended in PBS buffer containing Nuclei A < RTI ID = 0.0 > A. < / RTI > Cells were then analyzed using a FACS Calibur flow cytometer (Becton & Dickinson Co., USA).
As shown in FIG. 2, apoptosis was observed in 37.97% of cells in the presence of t-BHP, whereas apoptosis occurred in 9.16% (CCF 0.05 mg / mL) in dose- , 7.56% (CCF 0.1 mg / mL) and 5.99% (CCF 0.2 mg / mL). Similar treatment with 0.05 mg / mL of silymarin was observed when treated with 0.2 mg / mL of CCF.
Thus, it has been shown that Mandrel flower extract has significant hepatocyte protective effect against t-BHP causing oxidative damage.
3. Measurement of mitochondrial membrane potential (MMP)
Opening of mitochondrial permeability pore (MPT pore) and loss of mitochondrial membrane potential (MMP) are associated with oxidative cell death caused by t-BHP.
We investigated whether Mandra flower extract inhibited depolarization of mitochondria caused by t-BHP. The depolarization phenomenon of mitochondrial membrane, which means MMP loss, was analyzed by measuring rhodamine 123 fluorescent dye using flow cytometry analyzer.
As described above, Rhodamine 123 was added to the cell culture solution and treated at 37 ° C for 30 minutes so that the final concentration of the Rhodamine 123 was 10 μM. Cells were harvested, washed twice with PBS and analyzed with a flow cytometer.
(CCF 0.05 mg / mL) and 85% (CCF 0.1 mg / mL) in the pretreatment with CCF water extract, respectively. However, the concentration of Rhodamine 123 And 88% (CCF 0.2 mg / mL), indicating an increase in fluorescent cells stained with Rhodamine 123 (see FIG. 3). This suggests that the bamboo shoot extract protected the mitochondrial membrane from oxidative damage induced by t-BHP.
4. ROS Measurement
In order to confirm the reduction of oxidative stress caused by t-BHP in Chang cells, the occurrence of intracellular ROS was measured by DCFH-DA fluorescence method.
Chang liver cells were inoculated into a 96 well black plate at a concentration of 4 × 10 5 cells / mL. Cells were treated with water extracts and silymarin of various concentrations of Bombyx mori, and incubated for 1 hour. Then, 200 μM of t-BHP was added and left for 30 minutes. Control cells were also treated with DCFH-DA (5 μg / ml) for 30 min at 37 ° C. The DCFH-DA dye is freely transferable into cells and is hydrolyzed with 2'7-dichlorofluorescein (DCFH) by the intracellular esterase and trapped in the cell. The oxidation of DCFH in the presence of ROS leads to 2 '7-dichlorofluorescein (DCF) is formed.
As a result, the level of oxidant in the cell rapidly increased after treatment with t-BHP (200 μM, 30 min), whereas the cell treated with CCF water extract showed a decrease in the occurrence of ROS (see FIG. 4).
Therefore, it was found that ROS caused by oxidative damage caused by t-BHP in Chang cells decreased dose-dependently in the treatment of Mandrel flower extract.
Experimental Example 6. Experimental animal preparation and experiment
Five-week-old male Sprague-Dawley rats (body weight: 200 ~ 220 g) were purchased from Samtako Bio Korea Co. (Gyeonggi, Korea) and supplemented with standard rodent diet (Samyang Feed Co., Ltd., Incheon, Korea) Drinking water was provided for free consumption. Before the experiment, the light-dark period of 12 hours-12 hours was maintained at 55 ± 5% and 23 ± 1 ° C for at least one week.
The rats were divided into 6 groups (n = 6) to conduct an acute hepatotoxicity experiment. In group 1, CCF extract was administered at 100 mg / kg for 5 days. In group 3, CCF extract was administered at 500 mg / kg for 5 days. In
On
1. Evaluation of liver toxicity
Liver enzymes GOT and GPT were used as markers for early acute liver injury. The activities of GOT and GPT were analyzed by colorimetric method, and TG was analyzed using a commercial assay kit.
2. Lipid peroxidation
Lipid peroxidation was assayed using thiobarbituric acid (TBA) -active substances (TBARS) and tested with a slight modification of the previously reported method (Kamal et al. , 1989).
100 μL of the cell extract or standard solution was added to 200 μL of 10% trichloroacetic acid (TCA), left on ice for 15 minutes, centrifuged (3,000 g, 20 minutes) and 100 μL of the supernatant was added to 0.67% thiobarbituric acid (TBA), heat-treated at 100 ° C for 10 minutes, cooled with ice, and then measured with a spectrophotometer at 535 nm. The measurement results were compared with the 1,1,3,3-tetraethoxypropane (TEP) standard curve, and the total protein was used as a standard for bovine serum albumin.
As a result, serum GOT and GPT levels increased in single treatment of t-BHP (2 mmol / kg), and hepatic toxicity was observed in experimental rats. However, serum GOT and GPT levels decreased in dose- (See Table 4).
In addition, MDA (malondialdehyde) level and TG (triglyceride) level for liver lipid peroxidation measurement after t-BHP (2 mmol / kg) treatment were analyzed to confirm oxidative stress by t-BHP, (2 mmol / kg), while the liver lipid peroxidation induced by t-BHP was significantly reduced in the pretreatment of CCF water extracts (see Table 4).
These results suggest that Mandrel flower extract has an effect of protecting the liver from oxidative stress caused by t-BHP in the early stage.
The data were expressed as the mean ± standard deviation of the repeated measures and the analysis of variance (ANOVA) with Tukey's tests (GraphPad Prism 5) p < 0.05).
Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (7)
Wherein said Mandra flower extract comprises polyphenols and flavonoids.
Characterized in that the composition comprises from 0.1 to 50% by weight of a Mandrake flower extract.
The Mandrel flower extract comprises (1) washing and freeze-drying Celosia cristata L. by removing seeds; (2) adding water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof to the lyophilized dried flower of the mandrmia flower; And (3) filtering the extract of the extracted Mandrel flower to evaporate the filtrate and freeze-dry the extract.
In step (2), the mixture of water and water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof is mixed and extracted at a ratio of 8: 1 to 12: 1 (g / L).
Wherein the composition further comprises a food-acceptable extract, a nutritional component or a food-aid additive and is used as a health functional food.
Wherein the composition further comprises a pharmaceutically acceptable carrier or excipient and is used as a medicament effective for liver protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130055827A KR20140135488A (en) | 2013-05-16 | 2013-05-16 | Antioxidant composition comprising cockscome flower extracts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130055827A KR20140135488A (en) | 2013-05-16 | 2013-05-16 | Antioxidant composition comprising cockscome flower extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140135488A true KR20140135488A (en) | 2014-11-26 |
Family
ID=52456248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20130055827A KR20140135488A (en) | 2013-05-16 | 2013-05-16 | Antioxidant composition comprising cockscome flower extracts |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140135488A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160118506A (en) | 2015-04-02 | 2016-10-12 | 구을리주식회사 | Pharmaceutical Composition Comprising an Extract of Celosia for Preventing and Treating Fish Disease Caused by Virues |
| KR102050663B1 (en) * | 2018-05-24 | 2019-11-29 | 동의대학교 산학협력단 | Manufacturing method of makgeolli containing cockscomb extract |
| KR20200129889A (en) * | 2019-05-10 | 2020-11-18 | 동의대학교 산학협력단 | Functional food composition containing black kelp |
| CN114478700A (en) * | 2022-02-22 | 2022-05-13 | 南京医科大学 | Preparation method of urticaceae cyclic peptide in cockscomb seeds and application of urticaceae cyclic peptide in antitumor drugs |
| KR20230124846A (en) | 2022-02-17 | 2023-08-28 | 주식회사 나인비 | Composition for preventing, treating or improving obesity or fatty liver comprising extract of Celosia cristata flower as an active ingredient |
-
2013
- 2013-05-16 KR KR20130055827A patent/KR20140135488A/en not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160118506A (en) | 2015-04-02 | 2016-10-12 | 구을리주식회사 | Pharmaceutical Composition Comprising an Extract of Celosia for Preventing and Treating Fish Disease Caused by Virues |
| KR102050663B1 (en) * | 2018-05-24 | 2019-11-29 | 동의대학교 산학협력단 | Manufacturing method of makgeolli containing cockscomb extract |
| KR20200129889A (en) * | 2019-05-10 | 2020-11-18 | 동의대학교 산학협력단 | Functional food composition containing black kelp |
| KR20230124846A (en) | 2022-02-17 | 2023-08-28 | 주식회사 나인비 | Composition for preventing, treating or improving obesity or fatty liver comprising extract of Celosia cristata flower as an active ingredient |
| CN114478700A (en) * | 2022-02-22 | 2022-05-13 | 南京医科大学 | Preparation method of urticaceae cyclic peptide in cockscomb seeds and application of urticaceae cyclic peptide in antitumor drugs |
| CN114478700B (en) * | 2022-02-22 | 2023-09-08 | 南京医科大学 | Preparation method of nettle type cyclic peptide in cockscomb seed and application of nettle type cyclic peptide in anti-tumor drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luqman et al. | Experimental assessment of Moringa oleifera leaf and fruit for its antistress, antioxidant, and scavenging potential using in vitro and in vivo assays | |
| Carvalho et al. | Human cancer cell antiproliferative and antioxidant activities of Juglans regia L. | |
| AU2007217003B2 (en) | Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production | |
| KR20140135488A (en) | Antioxidant composition comprising cockscome flower extracts | |
| JP4730642B2 (en) | Active oxygen scavenger and composition thereof | |
| KR20090043656A (en) | An antioxidant composition comprising extracts of hippocampus kuda | |
| US20200337986A1 (en) | Dahlia pinnata composition, dahlia pinnata composition powder, cosmetic composition, and producing method therefor | |
| Roy et al. | Evaluation of cytotoxic activity of Piper betle Linn. using murine and human cell lines in vitro | |
| Shirwaikar et al. | In vitro free radical scavenging potential of defatted ethanolic extract of the seeds of Lepidium sativum Linn. | |
| KR20150051597A (en) | Food Composition for improving liver function containing extract of Arctiumlappa L. | |
| KR101906856B1 (en) | Novel composition comprising Chrysanthemum zawadskii | |
| KR20160141463A (en) | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis | |
| Bell et al. | In vivo antioxidant activity of bark extract of Bixa orellana L. against acetaminophen–induced oxidative stress | |
| Mirzaei et al. | Hepatoprotective effect and antioxidant activity of aqueous cherry extract on rats | |
| JPH0840923A (en) | Nutrient-supplying agent | |
| ES2779984B2 (en) | Procedure to identify properties of a grape extract | |
| Kim et al. | Antioxidant activity and protective effects of Uncaria rhynchophylla extracts on t-BHP-induced oxidative stress in Chang cells | |
| Mohd-Yazid et al. | Preliminary evaluation of antioxidant and cytotoxic activity of ethanolic extract of stingless bees propolis from different localities | |
| Oloyede et al. | Prevention of Fe 2+ induced lipid peroxidation by aqueous extract of Garcina kola leaf in some rat tissues | |
| EP1510137A1 (en) | Pyruvate enriched onion extract | |
| KR20140147949A (en) | Antioxidant composition comprising aloe vera extracts | |
| KR20150046777A (en) | Antioxidant composition comprising aloe vera extracts | |
| KR101436214B1 (en) | Food composition for enhancing alcohol degradation and curing hangover comprising extract of jujube leaves | |
| Afolabi et al. | Antagonistic potentials of Talinum triangulare extracts against iron II–induced oxidative stress in tissue homogenates of wistar albino rat-in vitro | |
| Tulsawani et al. | Effect of storage temperature on bio-efficacy of aqueous extract of Ganoderma lucidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |